December 6, 2023

As we delve deep into countless medical journals to uncover the latest on Integrative Medicine’s approach to kidney health, we are always reminded of the value of your time. Our commitment remains steadfast in curating and succinctly summarizing these vital studies for you. Welcome to the December Research and News.

 

Happy Holidays!

 

December Research and News

Beta-Hydroxybutyrate Levels and Kidney Function in ADPKD

In a novel study published by Knol et al., researchers explored the relationship between beta-hydroxybutyrate ketone levels and kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

The study, involving 670 patients from the DIPAK cohort, found that higher endogenous plasma beta-hydroxybutyrate concentrations might be associated with a slower decline in kidney function, as indicated by the estimated glomerular filtration rate (eGFR).

Why is this important?

This finding is significant as it suggests a potential metabolic intervention for ADPKD, a condition where cystic cells predominantly depend on glucose and have limited ability to use other energy sources like ketone bodies.

Interventions that elevate beta-hydroxybutyrate concentration could potentially slow down the rate of kidney function decline in ADPKD patients. These interventions may include a modified Ketogenic diet and intermittent fasting.

Read the study.
Sign up for Integrative Kidney Research & News from the Integrative Kidney Institute 


Prevalence of Sleep Apnea in CKD and ESKD Patients: A Comprehensive Meta-Analysis

A systematic review and meta-analysis conducted by Pisano et al. have brought to light the prevalence of sleep apnea (SA) in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD).

This extensive study, which synthesized data from 32 individual studies for CKD and 91 studies for ESKD, found that SA is highly prevalent in these populations, with rates of 57% in CKD and 49% in ESKD patients.

Notably, the prevalence assessed through instrumental sleep monitoring was found to be significantly higher than that estimated using sleep questionnaires.

Why is this important?

The high prevalence of sleep apnea in CKD and ESKD patients underscores a critical aspect of patient management that often might be overlooked.

This association points towards a need for more vigilant screening and diagnosis of SA in these populations, preferably using objective diagnostic tools like polysomnography or portable sleep monitors rather than relying solely on sleep questionnaires.

Identifying and treating SA in CKD and ESKD patients could improve overall health outcomes, considering the potential impact of untreated SA on cardiovascular health and quality of life.

CKD may lead to SA through a variety of mechanisms, including alterations in chemoreflex responsiveness, pharyngeal narrowing due to fluid overload, and accumulation of uremic toxins. It is also being increasingly recognized that OSA can also accelerate the loss of kidney function.

Read the study.

 

KetoCitra

 


Phosphate Wasting as a Predictor of Disease Progression in ADPKD

A recent study by Xue et al. in the DIPAK cohort has unveiled significant findings regarding phosphate metabolism in Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Analyzing 604 ADPKD patients, the study observed that a considerable proportion (59%) exhibited phosphate wasting. This condition was associated with various factors, including male sex, eGFR, levels of fibroblast growth factor-23 (FGF-23), parathyroid hormone (PTH), and Copeptin.

More crucially, phosphate wasting correlated with a more rapid decline in eGFR and increased the risk of adverse kidney outcomes.

Why is this important?

This research provides valuable insights into the importance of phosphate metabolism in ADPKD, a disease typically characterized by cyst formation and kidney enlargement.

The association of phosphate wasting with accelerated disease progression in ADPKD indicates that it could serve as a potential biomarker for disease prognosis.

In fact, phosphate wasting, according to this study, can be an early sign of tubular dysfunction in patients with ADPKD. It can also lead to inflammation and faster progression of kidney disease.

Read the study.

 

ClearlyFiltered Oasis

 


Iron Levels and Cardiovascular Risk in CKD

In an observational analysis of the Chronic Kidney Disease Japan Cohort, Hasegawa et al. investigated the association between serum iron markers and cardiovascular disease (CVD) risk in patients with pre-dialysis chronic kidney disease (CKD).

The study included 1,416 patients and examined serum transferrin saturation and ferritin levels in relation to CVD events.

Patients with transferrin saturation below 20% had a higher risk of CVD and congestive heart failure.

Iron supplementation was associated with a more favorable cardiovascular-risk pattern among patients with lower transferrin saturation. However, this was not a randomized treatment trial, and residual confounding means it cannot establish that supplementation caused a reduction in risk.

Why is this important?

These findings highlight iron status as a potentially useful part of individualized cardiovascular assessment in CKD and support further investigation of the links between nutrient status and heart-kidney health.

They do not prove that iron supplementation prevents cardiovascular events or establish a universal recommendation to treat CKD patients without anemia. Decisions about iron treatment should consider the patient’s iron studies, hemoglobin, symptoms and clinical context rather than this study alone.

Read the study.

 

 


Review article of the month

Diet and Polycystic Kidney Disease

Polycystic Kidney Disease (PKD) is a hereditary condition characterized by the growth of cysts in the kidneys and other organs. This chronic and progressive disease has recently seen a growing interest in the potential of dietary modifications as a means to prevent or slow its progression.

While vasopressin-receptor agonists have been a novel pharmacological breakthrough, recent trials and clinical studies have also shed light on dietary-related therapeutic strategies.

This review compiles the current evidence on the impact of nutrients, foods, and dietary patterns on the growth and progression of PKD cysts.

It also discusses the existing evidence-based dietary care for PKD patients and outlines the potential for further development of evidence-based dietary interventions, highlighting their possible implications in managing and treating PKD.

You can download the full PDF here.

 

 


We would love to hear your feedback. Let us know what you think of these educational materials and if you like us to focus on specific topics. Please email us at info@inkidney.com.